Early Detection Research Network


This biomarker is also known as:
  • HE4,
  • WAP domain containing protein HE4-V4,
  • WAP four-disulfide core domain 2 [Precursor],
  • WFDC2,
  • epididymis-specific, whey-acidic protein type, four-disulfide core,
  • dJ461P17.6,
  • WAP5,
  • Major epididymis-specific protein E4,
  • epididymal protein 4,
  • EDDM4,
  • WAP four-disulfide core domain 2,
  • Epididymal secretory protein E4,
  • Putative protease inhibitor WAP5,


11 kDa protein that is a precursor to the epididymal secretory protein HE4; an inhibitor of an as yet unidentified protease. Highly expressed in a number of tumors cells lines, such ovarian, colon, breast, lung and renal cells lines.


There are no datasets associated with this biomarker.

QA State: Accepted
Type: Protein

The following organs have data associated with this biomarker…


Phase: Two
QA State: Under Review
Organ-specific information for this biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact the Informatics Center if you should have access to this biomarker.


Phase: Three
QA State: Accepted


Selected for study because of upregulation (mRNA) and overexpression (protein) studies in ovarian cancer.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. HE4 alone was not a strong predictor. In 2009 HE4 was FDA approved to monitor for ovarian cancer recurrence, but not for early detection.

Supporting Study Data

The following studies/protocols provide evidence supporting HE4 indications for the Ovary…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

Organ-Specific Resources

No organ-specific resources defined.

Version 5.0.2